Janssen submits in EMA teclistamab for multiple mieloma under accelerated assessment

The EMA has released its list of applications for new medicines under evaluation by the CHMP in March 2022, confirming the submission of Janssen Cilag's teclistamab to the Agency, with a procedure start date on 17 February 2022.

The list also confirms that teclistamab will be evaluated under accelerated assessment timelines by the EMA.

Teclistamab is a bispecific antibody generated using Genmab's DuoBody technology that targets CD3 and B-cell maturation antigen (BCMA, tumor necrosis factor receptor superfamily member 17), for the potential IV or SC injectable treatment of multiple myeloma (MM).

Fonte: EMA applications for new medicines under evaluation by the CHMP - March 2022 (As a reminder, this list only includes information for medicines whose applications have been validated and evaluation started at the time the data was extracted).